Cargando…

The Pharmacokinetics of Triheptanoin and Its Metabolites in Healthy Subjects and Patients With Long‐Chain Fatty Acid Oxidation Disorders

Long‐chain fatty acid oxidation disorders (LC‐FAODs) are a group of life‐threatening autosomal recessive disorders caused by defects in nuclear genes encoding mitochondrial enzymes involved in the conversion of dietary long‐chain fatty acids into energy. Triheptanoin is an odd‐carbon, medium‐chain t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Sun Ku, Gupta, Manju, Shi, Jack, McKeever, Kathleen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597155/ https://www.ncbi.nlm.nih.gov/pubmed/33789001 http://dx.doi.org/10.1002/cpdd.944

Ejemplares similares

Population Pharmacokinetics of Heptanoate in Healthy Subjects and Patients With Long‐Chain Fatty Acid Oxidation Disorders Treated With Triheptanoin
por: Lee, Sun Ku, et al.
Publicado: (2022)

Physiological Perspectives on the Use of Triheptanoin as Anaplerotic Therapy for Long Chain Fatty Acid Oxidation Disorders
por: Sklirou, Evgenia, et al.
Publicado: (2021)

Long-term experience with triheptanoin in 12 Austrian patients with long-chain fatty acid oxidation disorders
por: Zöggeler, Thomas, et al.
Publicado: (2021)

Effects of triheptanoin (UX007) in patients with long‐chain fatty acid oxidation disorders: Results from an open‐label, long‐term extension study
por: Vockley, Jerry, et al.
Publicado: (2020)

Triheptanoin: First Approval
por: Shirley, Matt
Publicado: (2020)

Randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy
por: Borges, Karin, et al.
Publicado: (2019)

Correction to: Triheptanoin: First Approval
por: Shirley, Matt
Publicado: (2020)

Exploring triheptanoin as treatment for short chain enoyl CoA hydratase deficiency
por: Engelstad, Kristin, et al.
Publicado: (2021)

Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients With X‐linked Hypophosphatemia
por: Lee, Sun Ku, et al.
Publicado: (2021)

Open‐label long‐term treatment of add‐on triheptanoin in adults with drug‐resistant epilepsy
por: Borges, Karin, et al.
Publicado: (2020)

No effect of triheptanoin on exercise performance in McArdle disease
por: Madsen, Karen L., et al.
Publicado: (2019)

Dietary management and major clinical events in patients with longchain fatty acid oxidation disorders enrolled in a phase 2 triheptanoin study
por: Vockley, Jerry, et al.
Publicado: (2020)

Metabolism and pharmacokinetics of medium chain fatty acids after oral administration of royal jelly to healthy subjects
por: Yamaga, Masayuki, et al.
Publicado: (2019)

Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency
por: Mochel, Fanny, et al.
Publicado: (2016)

Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials
por: Qi, Yulan, et al.
Publicado: (2018)

A randomized, controlled, double-blind, crossover trial of triheptanoin in alternating hemiplegia of childhood
por: Hainque, Elodie, et al.
Publicado: (2017)

Triheptanoin – Novel therapeutic approach for the ultra-rare disease mitochondrial malate dehydrogenase deficiency
por: Laemmle, Alexander, et al.
Publicado: (2021)

Long-term follow-up in an open-label trial of triheptanoin in GLUT1 deficiency syndrome: a sustained dramatic effect
por: Hainque, Elodie, et al.
Publicado: (2019)

Combination of triheptanoin with the ketogenic diet in Glucose transporter type 1 deficiency (G1D)
por: Avila, Adrian, et al.
Publicado: (2023)

Pharmacokinetics of Glutathione and Its Metabolites in Normal Subjects
por: Hong, Sae-Yong, et al.
Publicado: (2005)

Pharmacokinetics of Lidocaine and Its Metabolites Following Vaginal Administration of Lidocaine Gel to Healthy Female Subjects
por: Martell, Bridget, et al.
Publicado: (2016)

In-situ, long-term monitoring system for radioactive contaminants
por: Durham, J S, et al.
Publicado: (2002)

Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects
por: Tran, Jonathan Q., et al.
Publicado: (2020)

Triheptanoin Protects Motor Neurons and Delays the Onset of Motor Symptoms in a Mouse Model of Amyotrophic Lateral Sclerosis
por: Tefera, Tesfaye W., et al.
Publicado: (2016)

A randomized, double‐blind trial of triheptanoin for drug‐resistant epilepsy in glucose transporter 1 deficiency syndrome
por: Striano, Pasquale, et al.
Publicado: (2022)

Achieving a healthy home food environment: perspectives on parents’ nutrition education needs when living with food insecurity
por: Oliver, Tracy, et al.
Publicado: (2023)

Blood cytokine patterns suggest a modest inflammation phenotype in subjects with long‐chain fatty acid oxidation disorders
por: McCoin, Colin S., et al.
Publicado: (2019)

Propofol pharmacokinetics in young healthy Indian subjects
por: Puri, Avinash, et al.
Publicado: (2012)

Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects
por: Narasimhan, Narayana I, et al.
Publicado: (2013)

Effects of food on the pharmacokinetics of ponatinib in healthy subjects
por: Narasimhan, NI, et al.
Publicado: (2013)

The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects
por: Zong, Jian, et al.
Publicado: (2014)

Pharmacokinetics and Safety of Defibrotide in Healthy Japanese Subjects
por: Umemura, Kazuo, et al.
Publicado: (2016)

Pharmacokinetic Properties of Rivaroxaban in Healthy Human Subjects
por: Bratsos, Sosipatros
Publicado: (2019)

Effect of Cilostazol on the Pharmacokinetics of Simvastatin in Healthy Subjects
por: Kim, Jung-Ryul, et al.
Publicado: (2019)

Ataluren Pharmacokinetics in Healthy Japanese and Caucasian Subjects
por: Kong, Ronald, et al.
Publicado: (2019)

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects
por: Song, Ivy H., et al.
Publicado: (2016)

The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects
por: Li, Ting, et al.
Publicado: (2022)

Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects
por: Fouqueray, Pascale, et al.
Publicado: (2022)

The Influence of Cannabidiol on the Pharmacokinetics of Methylphenidate in Healthy Subjects
por: Markowitz, John S., et al.
Publicado: (2022)

Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects
por: Yang, Haijing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_opr6mn7rhbj8d8cts6kqouocgp